BioMarin Takes One Step Closer To Profitability With Positive GALNS Data
This article was originally published in The Pink Sheet Daily
The orphan drug company reported positive Phase III data on its candidate for patients with the rare disease MPS IV and expects to file GALNS for FDA approval in the first quarter.
You may also be interested in...
BioMarin is in the midst of a pivotal year, with several near-term data catalysts, the most important of which will be Phase III data on GALNS for the rare disease MPS IV.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.
Regeneron CEO Len Schleifer and President George Yancopoulos talked at the Stat Summit about launching their COVID-19 antibody cocktail and planning for the next pandemic.